Press coverage about Rosetta Genomics (NASDAQ:ROSG) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rosetta Genomics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.0518997596714 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Rosetta Genomics remained flat at $$0.43 on Thursday, according to Marketbeat Ratings. Rosetta Genomics has a 12-month low of $0.23 and a 12-month high of $2.75.
Rosetta Genomics Company Profile
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests.
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.